Molecular Testing

  • June 12, 2021  

    Improving Access to Genetic Testing and Counseling Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about eReach, a study investigating whether telehealth can provide improved access to genetic testing for people at risk for cancer.

    .

  • June 12, 2021  

    Decoding the Differences between At-Home and Medical Genetic Testing Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about how the cost, access, accuracy, privacy and other aspects of at-home genetic testing compare to medical genetic testing with a specialist. 

    .

  • June 12, 2021  

    Tumor Biology Matters Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Results from the Know Your Tumor program shows overall survival benefit for patients with an actionable alteration and who received a matched therapy, compared to those with an actionable alteration and who did not receive a matched therapy. 

    .

  • June 12, 2021  

    Multi-Site Precision Promise Study Opens Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Learn about Precision Promise, an adaptive multi-site clinical trial spearheaded by the Pancreatic Cancer Action Network.

    .

  • June 12, 2021  

    New Trial to Find Biomarkers to Guide Treatment Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: A new clinical trial is using precision medicine to identify the best individualized standard-of-care options for pancreatic cancer patients.

    .

  • April 28, 2021  

    How Can Detection of Tumor DNA in the Blood Aid Advanced Cancer Treatment?

    With: Alexey Aleshin, MD, MBAPaul Billings, MD, PhD

    As a tumor grows, it may shed fragments of its DNA into the patient’s bloodstream. After treatment, if part of the tumor remains or it begins to grow again, more of this circulating tumor DNA (ctDNA) may enter the blood. That raises the possibility that detecting ctDNA could help clinicians monitor molecular or minimal residual disease—cancer that remains after treatment and cannot be detected… Read more »

  • March 9, 2021  

    How an Expert Would Treat His Own Advanced Lung Cancer

    With: Jack West, MD

    A new cancer diagnosis is overwhelming. Patients often ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks lung cancer expert Howard (Jack) West, MD, how he would handle his own diagnosis of advanced lung cancer. Dr. West is a Princeton- and Harvard-educated oncologist with additional training and experience in Boston and Seattle focusing on lung cancer.… Read more »

  • January 29, 2021  

    Targeted Therapy for Hepatocellular Carcinoma Bookmark

    George Lundberg, MD

    This scientific review paper published in the journal Signal Transduction and Targeted Therapy discusses recent research into newer medications that show promise as targeted therapies for some cases of primary hepatocellular carcinoma, following molecular testing.

    .

  • December 4, 2020  

    What Is a Cancer Commons Options Report?

    With: Lola Rahib, PhD

    As a Cancer Commons Scientist, Lola Rahib, PhD, helps cancer patients and caregivers navigate treatment. Some of these patients receive a Cancer Commons Options Report. Here, our Curious Dr. George asks Dr. Rahib to share what goes into each Options Report. Curious Dr. George: Cancer Commons provides advanced cancer patients who seek information with additional options for them to consider, all free of charge. What does… Read more »

  • October 16, 2020  

    Molecular Profiling in Metastatic Colorectal Cancer Bookmark

    George Lundberg, MD

    Article from the academic journal Oncology, curated by Contributing Editor George Lundberg, MD, who notes:

    Molecular testing is essential to guide effective treatment in metastatic colorectal cancer. This academic review article provides a good overview of the topic.

    .